Literature DB >> 19443729

Effect of bimatoprost, latanoprost, and unoprostone on matrix metalloproteinases and their inhibitors in human ciliary body smooth muscle cells.

Yen Hoong Ooi1, Dong-Jin Oh, Douglas J Rhee.   

Abstract

PURPOSE: Matrix metalloproteinase (MMP)-mediated turnover of extracellular matrix (ECM) affects outflow resistance in the uveoscleral pathway. The balance of MMPs and tissue inhibitors of metalloproteinases (TIMPs) governs the rate of ECM turnover in many tissues. The hypothesis was that a differential effect on MMPs and TIMPs in ciliary body smooth muscle (CBSM) cells would relate to the relative intraocular pressure-lowering effectiveness of the prostaglandin analogues (PGAs) bimatoprost, latanoprost, and unoprostone.
METHODS: Human CBSM cells isolated from donor corneoscleral rims were incubated for 24 hours with control (0.015% ethanol in DMEM) or the free acid forms of bimatoprost (0.01 or 0.1 microg/mL), latanoprost (0.03 or 0.3 microg/mL), or unoprostone (0.145 or 1.45 microg/mL). Western blot analysis determined the relative protein concentrations of MMP-1, -2, -3. -9, and -24 as well as TIMP-1 through -4. Zymography measured the relative activity levels of MMP-1, -2, -3, and -9.
RESULTS: All PGAs increased MMP-1, -3, and -9. Bimatoprost and latanoprost did not change MMP-2. Unoprostone decreased MMP-2 (21% +/- 3%). On zymography, MMP-1 and -2 did not change. Bimatoprost and latanoprost increased MMP-9 activity by 75% +/- 27% and 75% +/- 24%, respectively. MMP-3 activity was not detected on zymography. All PGAs increased TIMP-3, but only unoprostone increased TIMPs1 and -4 by 100% +/- 20% and 61% +/- 11%, respectively. TIMP-2 was unchanged by bimatoprost and latanoprost, but decreased by unoprostone (35% +/- 8%).
CONCLUSIONS: Decreased MMP-2 with concurrent increases of TIMP-1 and -4 by unoprostone may explain the lower clinical efficacy of unoprostone. The MMP/TIMP balance relates to the observed intraocular pressure-lowering effectiveness in clinical studies with PGAs.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19443729     DOI: 10.1167/iovs.08-3356

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  14 in total

Review 1.  The trabecular meshwork in normal eyes and in exfoliation glaucoma.

Authors:  Carol A Rasmussen; Paul L Kaufman
Journal:  J Glaucoma       Date:  2014 Oct-Nov       Impact factor: 2.503

2.  A cross-sectional survey of the association between bilateral topical prostaglandin analogue use and ocular adnexal features.

Authors:  Mamta Shah; Grace Lee; Daniel R Lefebvre; Benjamin Kronberg; Stephanie Loomis; Stacey C Brauner; Angela Turalba; Douglas J Rhee; Suzanne K Freitag; Louis R Pasquale
Journal:  PLoS One       Date:  2013-05-01       Impact factor: 3.240

3.  Unoprostone reduces oxidative stress- and light-induced retinal cell death, and phagocytotic dysfunction, by activating BK channels.

Authors:  Kazuhiro Tsuruma; Yuka Tanaka; Masamitsu Shimazawa; Yukihiko Mashima; Hideaki Hara
Journal:  Mol Vis       Date:  2011-12-30       Impact factor: 2.367

4.  Correlations between Preoperative Angle Parameters and Postoperative Unpredicted Refractive Errors after Cataract Surgery in Open Angle Glaucoma (AOD 500).

Authors:  Wonseok Lee; Hyoung Won Bae; Si Hyung Lee; Chan Yun Kim; Gong Je Seong
Journal:  Yonsei Med J       Date:  2017-03       Impact factor: 2.759

5.  Role of prostaglandins and specific place in therapy of bimatoprost in the treatment of elevated intraocular pressure and ocular hypertension: A closer look at the agonist properties of bimatoprost and the prostamides.

Authors:  Scott D Smid
Journal:  Clin Ophthalmol       Date:  2009-12-29

6.  Ocular pharmacokinetics of bimatoprost formulated in DuraSite compared to bimatoprost 0.03% ophthalmic solution in pigmented rabbit eyes.

Authors:  Afshin Shafiee; Lyle M Bowman; Eddie Hou; Kamran Hosseini
Journal:  Clin Ophthalmol       Date:  2013-07-31

Review 7.  An evidence-based review of unoprostone isopropyl ophthalmic solution 0.15% for glaucoma: place in therapy.

Authors:  Derrick S Fung; Jess T Whitson
Journal:  Clin Ophthalmol       Date:  2014-03-10

8.  Bimatoprost, latanoprost, and tafluprost induce differential expression of matrix metalloproteinases and tissue inhibitor of metalloproteinases.

Authors:  Hiroshi Yamada; Masahiko Yoneda; Masahiko Gosho; Tomohiro Kato; Masahiro Zako
Journal:  BMC Ophthalmol       Date:  2016-03-08       Impact factor: 2.209

9.  Effect of prostaglandin analogs on matrix metalloproteinases and tissue inhibitor of metalloproteinases in eyelid muscle specimens.

Authors:  Sapir Karli; Juan Alfredo Ayala-Haedo; William J Feuer; Maria Fernandez; Sander Dubovy; Sara T Wester
Journal:  Clin Ophthalmol       Date:  2018-10-11

10.  Effects of sustained daily latanoprost application on anterior chamber anatomy and physiology in mice.

Authors:  Laura M Dutca; Danielle Rudd; Victor Robles; Anat Galor; Mona K Garvin; Michael G Anderson
Journal:  Sci Rep       Date:  2018-08-30       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.